Is BBIO or BCYC more undervalued in 2026?

CirclFi compares BridgeBio Pharma, Inc. (BBIO) and Bicycle Therapeutics plc (BCYC) using 13 institutional-grade valuation models. BBIO has a Quality of Company score of 6.5/10 while BCYC scores 6.1/10.

Which is a better buy — BBIO or BCYC?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BBIO and BCYC valuations compare?

BBIO at $66.26 and BCYC at $4.69 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BBIO vs BCYC Valuation Comparison 2026 — Intrinsic Value Analysis

BBIO

Pharmaceutical Preparations

BridgeBio Pharma, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$66.26

Last close

Models

8/13

Active

BCYC

Pharmaceutical Preparations

Bicycle Therapeutics plc

Quality

6.1

out of 10

Value Trap

SAFE

Price

$4.69

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	BBIO Fair Value	BBIO Upside	BCYC Fair Value	BCYC Upside
Bayesian DCF	Intrinsic	$19.97	-69.9%	$5.46	+16.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	—	—	$9.86	+110.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$63.52	-13.3%	$13.29	+176.8%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BBIO vs BCYC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BBIO vs BCYC — Which Stock Is More Undervalued?

BBIO scores higher with a 6.5/10 quality rating vs BCYC's 6.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BridgeBio Pharma, Inc. (BBIO) and Bicycle Therapeutics plc (BCYC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BBIO currently trades at $66.26 with a QOC of 6.5/10, while BCYC trades at $4.69 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).